Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

CPRX

Catalyst Pharmaceuticals Inc

Oct 23 • 12:12PM ET

21.20

Dollar change -0.26
Percentage change -1.21	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM AMLX SUPN ENTA ITCI PRTA RDUS XENE EGRX ALKS

| Held by: IJR VTI IWM CALF FBT VXF XBI IJT IWO SPSM

Index	RUT	P/E	39.74	EPS (ttm)	0.53	Insider Own	13.70%	Shs Outstand	107.12M	Perf Week	-2.17%
Market Cap	2.52B	Forward P/E	15.25	EPS next Y	1.39	Insider Trans	-2.47%	Shs Float	102.43M	Perf Month	3.41%
Income	68.15M	PEG	11.51	EPS next Q	0.30	Inst Own	75.11%	Short Float	5.62%	Perf Quarter	22.05%
Sales	434.48M	P/S	5.79	EPS this Y	74.29%	Inst Trans	1.38%	Short Ratio	5.76	Perf Half Y	40.21%
Book/sh	5.14	P/B	4.13	EPS next Y	26.59%	ROA	11.85%	Short Interest	5.75M	Perf Year	69.19%
Cash/sh	3.17	P/C	6.70	EPS next 5Y	3.45%	ROE	13.85%	52W Range	11.89 - 21.85	Perf YTD	26.12%
Dividend Est.	-	P/FCF	15.68	EPS past 5Y	-	ROI	11.14%	52W High	-2.97%	Beta	0.77
Dividend TTM	-	Quick Ratio	4.94	Sales past 5Y	4106.79%	Gross Margin	78.33%	52W Low	78.30%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	5.14	EPS Y/Y TTM	-47.03%	Oper. Margin	19.77%	RSI (14)	58.78	Volatility	3.00% 2.56%
Employees	167	Debt/Eq	0.01	Sales Y/Y TTM	43.42%	Profit Margin	15.69%	Recom	1.00	Target Price	30.29
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-1.51%	Payout	0.00%	Rel Volume	0.35	Prev Close	21.46
Sales Surprise	9.74%	EPS Surprise	44.74%	Sales Q/Q	23.23%	Earnings	Nov 06 AMC	Avg Volume	998.39K	Price	21.20
SMA20	3.68%	SMA50	4.50%	SMA200	26.36%	Trades		Volume	155,734	Change	-1.21%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-24	Initiated	Citigroup	Buy	$27
Mar-07-24	Initiated	BofA Securities	Buy	$23
Dec-21-23	Initiated	Oppenheimer	Outperform	$30
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
Dec-15-08	Initiated	Merriman Curhan Ford	Buy

Show Previous Ratings

Oct-22-24 08:03AM	Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-08-24 08:03AM	Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts (GlobeNewswire)
Oct-01-24 12:00PM	Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:03AM	Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 (GlobeNewswire)
Sep-24-24 06:00AM	Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan (GlobeNewswire)
01:00AM	Loading…
Sep-12-24 01:00AM	Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report? (Zacks)
Aug-22-24 07:01PM	Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ... (GuruFocus.com)
Aug-20-24 08:03AM	Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-24 09:55AM	Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High? (Zacks)
Aug-07-24 08:30PM	Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +12.75%
07:40PM	Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:36PM	Catalyst: Q2 Earnings Snapshot (Associated Press Finance)
04:11PM	Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-24-24 08:05AM	Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada (GlobeNewswire)
08:03AM	Loading…
Jul-22-24 08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jun-07-24 11:30AM	Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report? (Zacks)
May-30-24 01:41PM	Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE (GlobeNewswire)
May-28-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-15-24 08:00AM	2 Incredible Growth Stocks to Buy Hand Over Fist Right Now (Motley Fool)
May-10-24 05:20PM	Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:40AM	Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues (Zacks) +6.32%
May-08-24 05:04PM	Catalyst: Q1 Earnings Snapshot (Associated Press Finance)
04:16PM	Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:00AM	Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
Apr-25-24 01:00AM	Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May (GlobeNewswire)
Apr-24-24 01:45PM	Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026 (InvestorPlace)
Apr-22-24 08:00AM	Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
11:30AM	Loading…
Mar-29-24 11:30AM	Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? (Zacks)
Mar-28-24 08:03AM	Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day (GlobeNewswire)
Mar-27-24 08:03AM	Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
Mar-14-24 02:00AM	Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE (Vamorolone) in the United States (GlobeNewswire)
Mar-13-24 07:55AM	Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-10-24 03:24PM	3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio (InvestorPlace)
Mar-05-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Feb-29-24 12:10PM	Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks) +10.10%
Feb-28-24 07:20PM	Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:35PM	Catalyst: Q4 Earnings Snapshot (Associated Press Finance)
06:03PM	Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 08:03AM	Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE (GlobeNewswire)
Feb-21-24 09:00AM	Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE ) Study Results in the Peer-Reviewed Journal Neurology (GlobeNewswire)
Feb-14-24 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Jan-18-24 09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-14-24 08:40AM	Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 (Motley Fool)
Jan-12-24 09:45AM	Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term (Zacks)
Jan-09-24 04:57PM	Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
04:05PM	Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jan-08-24 08:55AM	3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January (InvestorPlace)
Jan-05-24 08:02AM	Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.85%
Jan-04-24 04:49PM	Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Dec-18-23 06:30AM	Catalyst Pharmaceuticals Announces FIRDAPSE New Drug Application Submitted in Japan by Partner DyDo Pharma (GlobeNewswire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-08-23 11:30AM	Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report? (Zacks)
Dec-05-23 08:03AM	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies (GlobeNewswire) -5.38%
Dec-04-23 08:03AM	Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions (GlobeNewswire)
Nov-16-23 08:05AM	Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-09-23 06:10AM	Catalyst: Q3 Earnings Snapshot (Associated Press Finance)
Nov-08-23 04:11PM	Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Nov-02-23 10:37AM	Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE (GlobeNewswire)
10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
Nov-01-23 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-30-23 08:03AM	Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo (GlobeNewswire)
Oct-26-23 03:19PM	Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals (GlobeNewswire)
Oct-23-23 08:03AM	Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-19-23 08:03AM	Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer (GlobeNewswire)
Oct-16-23 08:03AM	Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida (GlobeNewswire)
Oct-13-23 08:03AM	Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE (GlobeNewswire)
Oct-12-23 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:40AM	This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar (Zacks)
Sep-18-23 08:03AM	Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-08-23 11:30AM	Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report? (Zacks)
Sep-06-23 01:06PM	Unraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metrics (GuruFocus.com)
Aug-16-23 10:56AM	Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer (GlobeNewswire)
Aug-14-23 08:05AM	Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress (GlobeNewswire)
Aug-11-23 06:09AM	Catalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022) (Simply Wall St.)
Aug-09-23 05:50PM	Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates (Zacks) +6.37%
04:41PM	Catalyst: Q2 Earnings Snapshot (AP Finance)
04:17PM	Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 02:44PM	7 Strong Buy Value Stocks You Should Be Loading Up On Now (InvestorPlace)
Jul-25-23 08:03AM	Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End (GlobeNewswire)
Jul-24-23 08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-23-23 10:21AM	Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.)
Jul-19-23 06:00AM	Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jul-05-23 05:50PM	Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-02-23 01:46PM	7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing (InvestorPlace)
Jun-29-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know (Zacks)
Jun-21-23 08:00PM	CPRX: Raising target price to $14.00 (Argus Research)
Jun-20-23 06:00AM	Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jun-19-23 09:30AM	Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Jun-14-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-09-23 11:30AM	Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 09:30AM	Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest? (Zacks)
08:03AM	Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023 (GlobeNewswire)

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tierney David S	Director	Aug 21 '24	Option Exercise	4.01	15,000	60,150	363,874	Aug 23 05:00 PM
Tierney David S	Director	Aug 21 '24	Sale	20.10	15,000	301,455	348,874	Aug 23 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 20 '24	Sale	20.35	150,000	3,052,900	675,124	Aug 22 05:00 PM
Tierney David S	Director	Aug 21 '24	Proposed Sale	20.10	15,000	301,450		Aug 21 02:21 PM
Miller Steve	Officer	Aug 20 '24	Proposed Sale	20.37	150,000	3,055,849		Aug 20 04:42 PM
Del Carmen Jeffrey	Chief Commercial Officer	Aug 09 '24	Option Exercise	2.86	30,000	85,800	42,369	Aug 13 05:01 PM
Del Carmen Jeffrey	Chief Commercial Officer	Aug 09 '24	Sale	18.42	36,058	664,310	12,369	Aug 13 05:01 PM
INGENITO GARY	Chief Med. & Reg. Officer	Aug 09 '24	Option Exercise	4.01	100,000	401,000	151,391	Aug 13 05:01 PM
INGENITO GARY	Chief Med. & Reg. Officer	Aug 09 '24	Sale	18.04	100,000	1,804,000	51,391	Aug 13 05:01 PM
INGENITO GARY	Officer	Aug 09 '24	Proposed Sale	18.03	100,000	1,803,262		Aug 09 02:53 PM
Del Carmen Jeffrey	Officer	Aug 09 '24	Proposed Sale	18.42	36,058	664,348		Aug 09 11:24 AM
Del Carmen Jeffrey	Chief Commercial Officer	Jun 07 '24	Sale	16.07	7,541	121,184	18,427	Jun 11 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Option Exercise	4.01	80,000	320,800	131,391	Jun 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Sale	16.16	80,000	1,292,800	51,391	Jun 07 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Option Exercise	4.01	40,000	160,400	252,147	Jun 05 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Sale	15.97	17,323	276,735	234,824	Jun 05 05:00 PM
Harper Molly	Director	Jun 03 '24	Sale	16.30	5,333	86,949	0	Jun 05 05:00 PM
Tierney David S	Director	Apr 08 '24	Option Exercise	4.01	25,000	100,250	373,874	Apr 10 05:15 PM
Tierney David S	Director	Apr 08 '24	Sale	15.68	25,000	392,000	348,874	Apr 10 05:15 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 27 '24	Sale	16.44	25,000	411,000	124,433	Mar 28 04:45 PM
DENKHAUS DONALD A	Director	Feb 05 '24	Option Exercise	4.01	40,000	160,400	434,333	Feb 06 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Jan 02 '24	Option Exercise	1.13	250,000	282,500	4,385,256	Jan 03 05:19 PM
Tierney David S	Director	Jan 02 '24	Option Exercise	1.13	10,000	11,300	344,874	Jan 03 05:19 PM
O'Keeffe Charles B	Director	Jan 02 '24	Option Exercise	1.13	60,000	67,800	681,724	Jan 03 05:18 PM
Harper Molly	Director	Dec 15 '23	Option Exercise	5.78	10,000	57,800	10,000	Dec 19 05:00 PM
Harper Molly	Director	Dec 15 '23	Sale	14.39	14,000	201,420	0	Dec 19 05:00 PM
Tierney David S	Director	Dec 12 '23	Option Exercise	1.13	50,000	56,500	383,541	Dec 14 05:00 PM
Tierney David S	Director	Dec 12 '23	Sale	13.32	50,000	666,250	333,541	Dec 14 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 11 '23	Option Exercise	1.13	150,000	169,500	797,457	Dec 13 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 11 '23	Option Exercise	1.13	60,000	67,800	110,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 08 '23	Option Exercise	1.13	40,000	45,200	90,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 11 '23	Sale	13.76	60,000	825,780	50,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 08 '23	Sale	14.28	40,000	571,000	50,557	Dec 12 05:00 PM
Daly Richard J	Director	Dec 07 '23	Option Exercise	1.13	60,000	67,800	208,000	Dec 11 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Dec 06 '23	Option Exercise	1.13	50,000	56,500	88,367	Dec 08 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Dec 06 '23	Sale	14.02	50,000	701,000	38,367	Dec 08 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 05 '23	Sale	14.24	40,000	569,600	647,457	Dec 07 05:00 PM

Open in Screener

ZVRA

Zevra Therapeutics Inc

Oct 23 • 12:12PM ET

8.06

Dollar change -0.28
Percentage change -3.40	%

Healthcare • Biotechnology • USA • NASD

ZVRA Zevra Therapeutics Inc daily Stock Chart

Peers: VRTX GILD ALNY REGN BMRN IONS NBIX SRPT EXEL BLUE

| Held by: VTI IWM VXF IWO IWN VTWO SURI IWC ITOT RSSL

Index	RUT	P/E	-	EPS (ttm)	-1.68	Insider Own	0.61%	Shs Outstand	52.62M	Perf Week	-4.77%
Market Cap	423.92M	Forward P/E	-	EPS next Y	-0.31	Insider Trans	7.54%	Shs Float	52.30M	Perf Month	-2.58%
Income	-65.75M	PEG	-	EPS next Q	-0.41	Inst Own	31.47%	Short Float	9.06%	Perf Quarter	29.11%
Sales	23.99M	P/S	17.67	EPS this Y	-21.56%	Inst Trans	15.99%	Short Ratio	4.23	Perf Half Y	75.90%
Book/sh	0.77	P/B	10.42	EPS next Y	80.33%	ROA	-52.61%	Short Interest	4.74M	Perf Year	91.36%
Cash/sh	0.75	P/C	10.80	EPS next 5Y	-	ROE	-130.22%	52W Range	3.89 - 8.95	Perf YTD	23.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	51.89%	ROI	-71.97%	52W High	-9.99%	Beta	1.96
Dividend TTM	-	Quick Ratio	2.00	Sales past 5Y	44.97%	Gross Margin	46.06%	52W Low	107.10%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	2.00	EPS Y/Y TTM	-77.61%	Oper. Margin	-309.83%	RSI (14)	52.42	Volatility	3.63% 6.32%
Employees	69	Debt/Eq	1.83	Sales Y/Y TTM	45.00%	Profit Margin	-274.10%	Recom	1.00	Target Price	20.43
Option/Short	Yes / Yes	LT Debt/Eq	1.81	EPS Q/Q	-217.07%	Payout	-	Rel Volume	0.39	Prev Close	8.34
Sales Surprise	1.92%	EPS Surprise	-5.73%	Sales Q/Q	-47.47%	Earnings	Aug 13 AMC	Avg Volume	1.12M	Price	8.06
SMA20	2.56%	SMA50	5.79%	SMA200	32.98%	Trades		Volume	196,630	Change	-3.40%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Initiated	Guggenheim	Buy	$20
Sep-24-24	Reiterated	Maxim Group	Buy	$18 → $25
Sep-24-24	Initiated	JMP Securities	Mkt Outperform	$17
Apr-02-24	Reiterated	Maxim Group	Buy	$12 → $18
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy	$12

Oct-10-24 07:30AM	Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.49%
Oct-09-24 06:19PM	Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
09:00AM	NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders (GlobeNewswire)
Sep-25-24 06:22AM	Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? (Zacks) -8.77%
Sep-24-24 07:30AM	Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 (GlobeNewswire) +9.10%
04:12AM	Loading…
Sep-23-24 04:12AM	FDA approves Zevra Therapeutics Miplyffa for Niemann-Pick disease (Pharmaceutical Technology) -5.96%
Sep-20-24 01:27PM	Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease (Benzinga)
12:08PM	Zevra Therapeutics' MIPLYFFA (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C (GlobeNewswire)
Sep-06-24 08:30AM	Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (GlobeNewswire)
Aug-29-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 05:30PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-09-24 12:00AM	Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -10.55%
Aug-08-24 04:01PM	Zevra Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:34AM	Loading…
Aug-07-24 09:34AM	Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire) -8.12%
Aug-06-24 10:00AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline (Zacks)
Aug-05-24 11:13AM	Zevra wins FDA panel backing for previously rejected arimoclomol (Pharmaceutical Technology) +25.08%
Aug-02-24 05:50PM	FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C (GlobeNewswire)
Jul-30-24 08:38AM	Zevra Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -5.82%
Jul-10-24 03:04PM	Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug (Zacks)
08:24AM	Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains? (Zacks)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 03:27PM	FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base (Benzinga) +21.94%
09:00AM	Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Jun-25-24 07:30AM	Zevra Therapeutics Expands Executive Leadership Team (GlobeNewswire)
Jun-18-24 07:30AM	Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders (PR Newswire)
Jun-03-24 11:00AM	Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting (GlobeNewswire)
May-09-24 12:24PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Events (GlobeNewswire)
03:03AM	Loading…
03:03AM	Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 11:57AM	ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:12AM	Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ... (GuruFocus.com)
08:15AM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-01-24 07:30AM	Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 (GlobeNewswire)
Apr-29-24 07:30AM	Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 (GlobeNewswire)
Apr-15-24 05:01PM	Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting (GlobeNewswire)
Apr-10-24 07:30AM	Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility (GlobeNewswire)
Apr-01-24 12:46PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.03%
Mar-29-24 12:07PM	Q4 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 09:52PM	ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -11.03%
06:11PM	Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ... (GuruFocus.com)
04:53PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:32PM	Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Mar-26-24 04:30PM	Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Mar-25-24 04:30PM	Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-24 10:00AM	Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-18-24 07:30AM	Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 (GlobeNewswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-04-24 07:30AM	Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) -12.15%
Feb-28-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-15-24 03:49AM	Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks) +8.79%
Feb-06-24 07:30AM	Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-23-24 07:30AM	Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors (GlobeNewswire)
Jan-08-24 07:30AM	Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) +6.90%
Jan-04-24 08:55AM	Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer (GlobeNewswire)
Dec-27-23 07:30AM	Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration (GlobeNewswire) +10.71%
Nov-20-23 07:30AM	Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company (GlobeNewswire)
Nov-12-23 08:42AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:17AM	Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results (GuruFocus.com)
07:08AM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 07:30AM	Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET (GlobeNewswire)
Oct-19-23 07:30AM	Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October (GlobeNewswire)
Oct-10-23 07:30AM	Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director (GlobeNewswire)
Oct-05-23 07:30AM	Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting (GlobeNewswire)
Oct-02-23 07:30AM	Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Sep-20-23 07:30AM	Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-23 08:00PM	Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023 (GlobeNewswire)
Sep-05-23 07:30AM	Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.51%
Sep-04-23 09:55AM	How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51% (Zacks)
Sep-01-23 07:31AM	Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up (Zacks) +6.11%
Aug-31-23 12:13PM	Struggling Newton biotech Acer Therapeutics scooped up by Florida firm (American City Business Journals)
07:30AM	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product (GlobeNewswire)
Aug-19-23 07:40AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-17-23 09:55AM	Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-15-23 12:15AM	Q2 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:42AM	Zevra Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 04:45PM	Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster (GlobeNewswire) +7.00%
Aug-02-23 07:30AM	Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023 (GlobeNewswire)
Jul-19-23 10:30AM	Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long (Simply Wall St.)
07:30AM	Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference (GlobeNewswire)
Jun-20-23 07:30AM	Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 (GlobeNewswire) +6.88%
Jun-13-23 07:30AM	Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest (GlobeNewswire)
Jun-03-23 07:30AM	Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 (GlobeNewswire)
May-16-23 06:22AM	Q1 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.11%
May-15-23 05:55PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Zevra Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 07:30AM	Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
May-09-23 07:30AM	Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023 (GlobeNewswire) -9.96%
May-08-23 07:30AM	Zevra Announces Board of Directors and Leadership Changes (GlobeNewswire)
May-03-23 07:30AM	Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy (GlobeNewswire)
Apr-17-23 04:05PM	Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevras Transformation Strategy (GlobeNewswire)
06:18AM	Why Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price Surge (Simply Wall St.)
Apr-04-23 07:30AM	Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy (GlobeNewswire)
Mar-30-23 07:30AM	Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors (GlobeNewswire)

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watton Corey Michael	Director	Oct 11 '24	Buy	7.92	500	3,958	1,500	Oct 16 04:46 PM
Clifton R. LaDuane	CFO & Treasurer	Jul 17 '24	Buy	6.77	2,000	13,540	18,469	Jul 17 05:54 PM
Anderson Thomas	Director	Jul 16 '24	Buy	6.81	10,000	68,065	20,000	Jul 16 04:39 PM
Bode John B	Director	Jul 12 '24	Buy	5.87	10,000	58,661	30,000	Jul 15 04:10 PM

CPRX

Catalyst Pharmaceuticals Inc

ZVRA

Zevra Therapeutics Inc

Upgrade your FINVIZ experience